Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10932246 | 1.00 | CYP2D6 (0.46) | CYP2D6SRCDPP4F2LMNA | |
| SCHEMBL8481256 | 1.00 | CYP2D6 (0.46) | CYP2D6SRCDPP4F2LMNA | |
| Hydrochloric Acid SCHEMBL2003210 | 0.98 | CYP2D6 (0.44) | CYP2D6SRCDPP4F2LMNA | |
| Hydrochloric Acid SCHEMBL6718139 | 0.98 | CYP2D6 (0.44) | CYP2D6SRCDPP4F2LMNA | |
| Hydrochloric Acid SCHEMBL9800501 | 0.98 | CYP2D6 (0.44) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL31402004 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL159420 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL30559595 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL11576917 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA | |
| Phenylglycine SCHEMBL157180 | 0.80 | CYP2D6 (0.56) | CYP2D6SRCDPP4F2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011138795-A2 | PROCESS FOR PREPARING (S)-10-ACETOXY-10,11-DIHYDRO-5H-DIBENZ[B,F] AZEPINE-5-CARBOXAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-11-10 | — | — | WO | claimed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| CN-102584762-A | Gelsemic acid derivative and preparation method and application thereof | UNIV CHINA PHARMA | 2012-07-18 | — | — | CN | disclosed |
| CN-1095846-C | Production process of cephem compound | EISAI KAGAKU KK (JP) | 2002-12-11 | — | — | CN | disclosed |
| EP-1075479-A1 | A METHOD FOR CRYSTALLIZING A BETA-LACTAM ANTIBIOTIC | DSM N.V. (NL) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999055710-A1 | A METHOD FOR CRYSTALLIZING A β-LACTAM ANTIBIOTIC | DSM N.V. (NL) | 1999-11-04 | — | — | WO | disclosed |
| CN-1184814-A | Production process of cephem compound | EISAI KAGAKU KK (JP) | 1998-06-17 | — | — | CN | disclosed |
| EP-0279125-B1 | TETRAHYDROPYRIDO(1,2-A)INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1992-04-29 | — | — | EP | disclosed |
| US-4968699-A | CENTRAL NERVOUS SYSTEM; ANTIISCHEMIC AND ANTIHYPOXIC AGENTS; ACTIVE AGAINST CEREBRAL OXYGEN DEFICIENCY | BEECHAM-WUELFING GMBH & CO. (DE) | 1990-11-06 | — | — | US | disclosed |
| US-4145343-A | BACTERICIDES | UCB SOCIETE ANONYME (BE) | 1979-03-20 | — | — | US | disclosed |
| US-4139628-A | ANTIBIOTICS | U C B, SOCIETE ANONYME (BE) | 1979-02-13 | — | — | US | disclosed |
| US-4137236-A | ANTIBIOTICS, BACTERICIDES | U C B, SOCIETE ANONYME (BE) | 1979-01-30 | — | — | US | disclosed |
| US-4079179-A | 6-Loweralkoxy or loweralkylthio-3-cephem-4-carboxylic acids | MERCK & CO., INC. (US) | 1978-03-14 | — | — | US | disclosed |
| US-4077967-A | 6-Substituted penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4071512-A | Preparation of 1-oxapenicillins and intermediates therefor | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1978-01-31 | — | — | US | disclosed |
| US-4005074-A | Process for cleaving an imido side chain from penicillins and cephalosporins | ELI LILLY AND COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
| US-4001239-A | CEPHALOSPORIN CLEAVAGE PROCESS | ELI LILLY AND COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3994888-A | Cephalosporin cleavage process | ELI LILLY AND COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
| US-3939270-A | INFECTIOUS DISEASES | ASTRA LAKEMEDEL AKTIEBOLAG (SW) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | CYP2D6 2350/4885SRC 3073/4885DPP4 1985/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | CYP2D6 2350/4885SRC 3073/4885DPP4 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.